{
    "clinical_study": {
        "@rank": "26827", 
        "arm_group": {
            "arm_group_label": "RO6864018", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "This randomized, double-blind, placebo-controlled, single ascending dose study will assess\n      the safety, pharmacokinetics, and pharmacodynamics of RO6864018 in healthy, male, asian and\n      caucasian volunteers. Volunteers will be enrolled in cohorts and randomized 8:2 to receive a\n      single oral administration of RO6864018 or placebo. Total study time, including treatment\n      and follow-up, is up to 9 weeks."
        }, 
        "brief_title": "A Single Ascending Dose Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of RO6864018 in Male, Healthy, Asian Volunteers", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Healthy Volunteer", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy male volunteers of ethnic Chinese, Korean, Japanese origin or Caucasian\n\n          -  21 to 65 years of age.\n\n          -  no signs of any active or chronic disease following a detailed medical and surgical\n             history, a complete physical examination including vital signs, 12-lead ECG,\n             hematology, blood chemistry, serology and urinalysis.\n\n          -  Body Mass Index (BMI) between 18 to 30 kg/m2 inclusive, and a weight range of 50 to\n             90 kg (110 to 198 lb) inclusive at screening.\n\n          -  Use of effective contraception, as defined by study protocol.\n\n          -  Non-smokers, or use of < 10 cigarettes (or equivalent nicotine-containing product)\n             per day.\n\n        Exclusion Criteria:\n\n          -  History or symptoms of any significant disease.\n\n          -  Personal or family history of congenital long QT syndrome or sudden death.\n\n          -  Any confirmed significant allergic reactions against any drug, or multiple drug\n             allergies (non-active hay fever is acceptable).\n\n          -  Positive results for anti-nuclear antibody (ANA), anti-mitochondrial antibody (AMA),\n             anti-smooth muscle antibody (ASMA) and thyroid peroxidase antibody.\n\n          -  Suspicion of regular consumption of drug of abuse.\n\n          -  History (within 3 months of screening) of alcohol consumption exceeding 14 units per\n             week on average (1 unit = 10 grams of alcohol).\n\n          -  Volunteers who have received IFN or peginterferon within 8 weeks prior to dosing.\n\n          -  Use of any medication (prescription or over the counter [OTC], including health\n             supplements and herbal remedies) within 2 weeks before the first dose of study\n             medication.\n\n          -  Donation or loss of blood of greater than 500 mL within 90 days prior to dosing.\n\n          -  Have participated in other clinical studies within 60 days prior to study\n             randomization."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "21 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 28, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02015715", 
            "org_study_id": "YP29017"
        }, 
        "intervention": {
            "arm_group_label": "RO6864018", 
            "description": "Single ascending oral doses.", 
            "intervention_name": "RO6864018", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "May 5, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Singapore", 
                    "country": "Singapore", 
                    "zip": "529889"
                }
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Singapore"
        }, 
        "number_of_arms": "1", 
        "official_title": "A PHASE I, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SINGLE ASCENDING DOSE STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF RO6864018 FOLLOWING ORAL ADMINISTRATION IN ASIAN HEALTHY SUBJECTS", 
        "overall_contact": {
            "email": "global.rochegenentechtrials@roche.com", 
            "last_name": "Reference Study ID Number: YP29017 www.roche.com/about_roche/roche_worldwide.htm", 
            "phone": "888-662-6728 (U.S. Only)"
        }, 
        "overall_official": {
            "affiliation": "Hoffmann-La Roche", 
            "last_name": "Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Singapore: Singapore Health Sciences Authority"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Incidence of adverse events", 
            "safety_issue": "No", 
            "time_frame": "Up to Day 29"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02015715"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Area under the plasma concentration-time curve (AUC) of RO6864018", 
                "safety_issue": "No", 
                "time_frame": "Days 1-3"
            }, 
            {
                "measure": "Area under the urine concentration-time curve of RO6864018", 
                "safety_issue": "No", 
                "time_frame": "Days 1-3"
            }, 
            {
                "measure": "Plasma immunoassay to evaluate pharmacodynamics", 
                "safety_issue": "No", 
                "time_frame": "Days 1-3"
            }, 
            {
                "measure": "Area under the plasma concentration-time curve (AUC) of RO6864018 values in healthy Caucasian volunteers versus in healthy Asian volunteers.", 
                "safety_issue": "No", 
                "time_frame": "Days 1-3"
            }
        ], 
        "source": "Hoffmann-La Roche", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hoffmann-La Roche", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}